Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The general head space of 3-MeO-PCMo is often described as simplistic and shallow in comparison to that of MXE and ketamine.
This substance does not enhance visual stimuli; instead, it tends to degrade and decrease visual aptitude in a variety of ways.
The visual geometry of 3-MeO-PCMo can be described as very dark and bland when compared to that of ketamine or DXM. It often consists of many tiny interlocking and woven lines. It does not extend beyond level 4 geometry and can be comprehensively described as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Chronic use can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence. Compulsive redosing is reported as a notable cognitive effect.
When addiction has developed, cravings and withdrawal effects may occur if usage is suddenly stopped, though the specific nature and severity of physical withdrawal has not been well characterized.
The exact toxic dosage is unknown as toxicity has not been studied in any scientific context.
Repeated heavy use, particularly on a daily or weekly basis, can cause bladder and urinary tract problems similar to those seen with ketamine but potentially more severe due to the compound's lower potency requiring larger quantities to achieve equivalent effects; symptoms include urinary frequency, urgency, pressure, pelvic and bladder pain, hematuria, and incontinence.
Mania is listed among potential cognitive effects. As with other dissociatives, there is risk of adverse psychological reactions including anxiety, mania, delusions, and psychosis, with these risks increasing at higher doses.
3-MeO-PCMo is a novel dissociative substance that emerged on the gray market as a designer drug in the mid-2010s. It became available primarily through online research chemical vendors, where it was marketed alongside other novel arylcyclohexylamines. As a relatively obscure compound, it has…
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production and import with intent to distribute, administration to others, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalties.
Controlled under the Psychoactive Substances Act 2016, which took effect on May 26, 2016. Production, supply, and importation are illegal. Notably, 3-MeO-PCMo falls outside the generic arylcyclohexylamine definition in the Misuse of Drugs Act 1971 because its morpholine substituent is not covered by that legislation. Simple possession outside of custodial institutions is not criminalized under the PSA.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation. Production, distribution, and possession without authorization are prohibited.
12 sources cited
